Breast Carcinoma
|
0.500 |
CausalMutation
|
disease |
CGI |
|
|
|
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Ecotropic virus, which normally does not infect human cells, when pseudotyped with the modified envelope protein now crosses species to infect human breast cancer cell lines that overexpress HER-2 (human epidermal growth factor receptor; also called ERBB2) and HER-4 (also called ERBB4), while human breast cancer cell lines expressing low levels of these receptors remain resistant to infection.
|
7568210 |
1995 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The significance of erbB-3 and erbB-4 in breast cancer is not yet known.
|
8764133 |
1996 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Due to these correlations, erbB-4 oncogene amplification can be assumed to be of prognostic or predictive value in the diagnosis of breast cancer.
|
9858771 |
1998 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The precise biological role of this oncogenic signaling pathway (which also involves the HER4 gene) in breast cancer is unclear.
|
9563896 |
1998 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Administration of heregulin-beta2 (HRG), a ligand for erbB3 and erbB4, to growth arrested T-47D human breast cancer cells leads to activation of both the PI3-kinase and MAP kinase signalling pathways and potent stimulation of cell cycle progression.
|
9652748 |
1998 |
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
c-erbB3 and c-erbB4 expression is a feature of the endocrine responsive phenotype in clinical breast cancer.
|
9788438 |
1998 |
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The highest level of erbB-4 expression was found in the ovarian carcinoma OVCAR-3 and the breast carcinoma T-47D.
|
9780009 |
1998 |
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Larger series with extended follow-up will be required to ascertain definitively the prognostic value of c-erbB-4 expression in breast carcinoma.
|
10735500 |
2000 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
However, c-erbB-4 antagonizes the c-erbB-2 effect on clinical course in breast carcinomas.
|
11748637 |
2002 |
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The expression pattern of c-erbB-4 in breast carcinomas is special.
|
12184370 |
2002 |
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
The expression of transcripts encoding the cleavable ErbB4 isoforms associated with estrogen receptor-alpha (ER) expression (P < 0.001) and a high histologic grade of differentiation (P </= 0.002) in real-time reverse transcription-PCR analysis of 62 breast cancer samples.
|
15735025 |
2005 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Heregulins are a family of ligands for the ErbB3/ErbB4 receptors that play important roles in breast cancer cell proliferation and tumorigenesis.
|
16428439 |
2006 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
HER4 in breast cancer: comparison of antibodies against intra- and extra-cellular domains of HER4.
|
16606438 |
2006 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Knockdown of BRCA1 with small interfering RNA in a human breast cancer cell line interfered with HER4-mediated mitotic delay.
|
16914727 |
2006 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
These data suggest a novel transforming mechanism for the ErbB4 receptor in human breast cancer that is 1) specific for a single receptor isoform and 2) depends on proteinase cleavage and kinase activity but not ligand activation of the receptor.
|
16251361 |
2006 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
We detected the ERBB4 somatic mutations in 3 of 180 gastric carcinomas (1.7%), 3 of 104 colorectal carcinomas (2.9%), 5 of 217 nonsmall cell lung cancers (2.3%) and 1 of 94 breast carcinomas (1.1%).
|
16187281 |
2006 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Thus, the roles that ErbB4 plays in human breast cancer are still poorly defined.
|
17120616 |
2006 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our results indicate that ERBB4 is a unique coregulator of ER, directly coupling extranuclear and nuclear estrogen actions in breast cancer.
|
16912174 |
2006 |
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In vitro, Wwox associated with the two ErbB4 isoforms, JM-a CYT-1 and JM-a CYT-2, expressed in breast cancer.
|
17909041 |
2007 |
Breast Carcinoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
In analysis of selected candidate cancer susceptibility genes, two MSR1 SNPs (rs9325782, GEE p = 0.008 and rs2410373, FBAT p = 0.021) were associated with prostate cancer and three ERBB4 SNPs (rs905883 GEE p = 0.0002, rs7564590 GEE p = 0.003, rs7558615 GEE p = 0.0078) were associated with breast cancer.
|
17903305 |
2007 |
Breast Carcinoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
These data indicate that EGFR as well as HER2 are prognostic factors of worse clinical outcomes, whereas HER3 and HER4 gene transcription is associated with better prognosis in high-risk early breast cancer.
|
18985033 |
2008 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
This review focuses on recent advances in our understanding about the role of ErbB4 in breast carcinogenesis, as well as in the potential clinical relevance of ErbB4 in breast cancer prognostics and therapy.
|
18454307 |
2008 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Overall, the simultaneous quantification of HER3 and HER4 receptor genes by means of FISH might enable the rendering of a more precise stratification of breast cancer patients by providing additional prognostic information.
|
18182100 |
2008 |
Breast Carcinoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In addition a developmental and temporal model of 4ICD action in the normal breast and during the progression of breast cancer will be presented to explain the paradox of divergent HER4 and 4ICD activities.
|
18473151 |
2008 |